רÀûÃû³Æ£º¸Ê±ûëÄÔÚÖÆ±¸Å®ÐÔÒÖÓôÖ¢¼ì²â¹¤¾ßÖеÄÓ¦ÓõÄÖÆ×÷·½·¨
¼¼ÊõÁìÓò£º
±¾·¢Ã÷Éæ¼°Ò»ÖÖÉúÎﻯѧÎïÖÊÔÚ¼²²¡¼ì²âÖеÄÐÂÓ¦Ó᣾ßÌå¶øÑÔ£¬±¾·¢Ã÷Éæ¼°ÈËѪ½¬Öиʱûëĵļì²â·½·¨ÒÔ¼°¸Ê±ûëÄÔÚÅ®ÐÔÒÖÓôÖ¢¼ì²âÖеÄÓ¦Óá£
±³¾°¼¼Êõ£º
ÒÖÓôÖ¢ÓÖ³ÆÒÖÓôÕϰ£¬ÊÇÓɸ÷ÖÖÔÒòÒýÆðµÄÒÔÒÖÓôΪÖ÷ÒªÖ¢×´µÄÐľ³Õϰ»òÇé¸ÐÐÔÕϰ£¬Éæ¼°ÒÅ´«¡¢Éú»¯¡¢ÐÄÀíºÍÉç»á»·¾³µÈ¶àÖÖÒòËØ¡£ÒÔ³ÖÐøÐÔÐľ³µÍÂäΪÖ÷ÒªÌØÕ÷£¬Ö÷Òª±íÏÖΪÇéÐ÷µÍÂä¡¢¾«ÉñѹÒÖ¡¢Ò×ÓÚ¿ÞÆü£¬¿É°éÓÐ×Ô±°¡¢×ÔÔ𣬻¼Õ߸е½¾«Á¦Æ£±¹¡¢ÄÔÁ¦³Ù¶Û¡¢Ç°Í¾°µµ¡¢±¯¹ÛʧÍûµÈ¡£ÒÖÓôÖ¢ÊôÓÚÖÐÒ½ÇéÖ¾²¡·¶³ë£¬É¢ÔÚÓÚ¹ÅÒ½¼®ÖÐÓôÖ¤¡¢ñ²¿ñ¡¢ÔàÔê¡¢°ÙºÏ²¡¡¢¾ª¼Â¡¢Õúâç¡¢²»Ã¡¢±¼ëàÆøµÈ¼²²¡¡£Ëæ×ÅÉç»áµÄ·¢Õ¹£¬Ó¦¼¤Ô´µÄÔö¶à£¬ÒÖÓôÖ¢µÄ·¢²¡ÂʳÊÖðÄêÔö³¤µÄÇ÷ÊÆ¡£Ñо¿ÏÔʾ£¬µ¥ÏàÒÖÓôµÄÖÕÉú»¼²¡ÂÊÔÚ10%ÒÔÉÏ£¬ÇÒÅ®ÐÔÊÇÄÐÐÔµÄ2±¶×óÓÒ[Moldin SO,Reich T,Rice JP.Current perspectives on the genetics of unipolardepression.Behav Genetl991 £»21 (3):211-242]¡£
ÒÖÓôÖ¢µÄ·¢²¡ÂÊ¡¢¸´·¢ÂÊ¡¢×ÔɱÖ²ÐÂʽϸߣ¬È´ÃæÁÙ׿ì³öÂʵ͡¢ÖÎÁÆÂʵÍÒÔ¼°ÖÎÓúÂʵ͵ÈÌØµã¡£ÊÀ½çÎÀÉú×éÖ¯Ô¤²â£¬µ½2020ÄêÒÖÓôÖ¢½«³ÉΪ·¢Õ¹Öйú¼Ò½ö´ÎÓÚÐÄÔಡµÄµÚ¶þ´ó¼²²¡£¬³ÉΪ×îÑÏÖØµÄ¼²²¡¸ºµ£[Kessler RC, Berglund P, Demler 0.The epidemiologyof major depressive disorder:results from the national comorbidity surveyreplication (NCS-R).JAMA2003£¬89(2):3095]¡£
ÒÅ´«Ñо¿ÈÏΪ£¬ÒÖÓôÖ¢¾ßÓÐÒ»¶¨µÄÒÅ´«ÇãÏò¡£Ë«Éú×ÓÑо¿ÏÔʾ£¬ÒÖÓôÖ¢µÄÒÅ´«¶ÈÔÚ40% 50% [Torgersen S.Genetic factors in moderately severe and mild affectivedisorders.Arch Gen Psychiatryl986 ;43 (3):222-226]¡£¼ÄÑø×ÓÑо¿Ò²Ìá²»ÒÅ´«ÔÚÒÖÓôÖ¢·¢²¡ÖоßÓÐÖØÒª×÷ÓÃ[Wender PHiKety SS, Rosenthal D, Schulsinger F, Ortmann J, Lunde1.Psychiatric disorders in the biological and adoptive families of adoptedindividuals with affective disorders.Arch Gen Psychiatryl986 £»43(10):923-929]¡£ÒÖÓôÖ¢ÏÈÖ¤ÕßÒ»¼¶Ç×ÊôÓëÆÕͨÈËȺÏà±È£¬ÆäÏà¶ÔΣÏÕ¶ÈÔÚ2 3£¬¸´·¢ÐÔÒÖÓôºÍÔç·¢ÒÖÓôµÄÏà¶ÔΣÏÕ¶ÈÖÁÉÙÔÚ4 5¡£µ«Æù½ñΪֹ£¬ÒÖÓôÖ¢µÄÒÅ´«Ä£Ê½»¹²»ÉõÇå³þ¡£
Ô´ÓÚµ¥°·Ñõ»¯Ã¸ÒÖÖÆ¼Á[RichelsonE.Synaptic effects of anti depressants.JClin Psychopharmacol 1996 £»16 (3Suppl2):1S_7S]ºÍÈý»·À࿹ÒÖÓôÒ©[Tran PV£¬BymasterFP, McNamara RK, Potter WZ.Dual monoamine modulation for improved treatment ofmajor depressive disorder.J Clin Psychopharmacol2003 £»23(1):78-86]ͨ¹ýÔö¼ÓÍ»´¥¼ä϶ȥ¼×ÉöÉÏÏÙËØ(È¥¼×ÉöÉÏÏÙËØ)ºÍ5ôÇÉ«°·(ÎåôÇÉ«°·)Ũ¶È¶ø·¢»Ó¿¹ÒÖÓôЧӦµÄµ¥°·µÝÖʼÙ˵ÊÇÒÖÓôÖ¢²¡ÒòѧµÄÖ÷Á÷¼Ù˵[Chopra K£¬Kumar B£¬Kuhad A.Pathobiologicaltargets of depression.Expert Opin Ther Targets 2011 £»15 (4):379-400]¡£¼Ù˵ÈÏΪ£¬ÒÖÓôÖ¢ÊÇÖÐÊàÈ¥¼×ÉöÉÏÏÙËØºÍÎåôÇÉ«°·¹¦Äܲ»×ã»òȱʧËùÖ¡£´óÁ¿Ö¤¾Ý±íÃ÷:ÖÐÊàÎåôÇÉ«°·ºÍÈ¥¼×ÉöÉÏÏÙËØ¹¦ÄÜʧµ÷ÓëÒÖÓôÖ¢·¢²¡ÒÔ¼°¿¹ÒÖÓôÒ©µÄ×÷ÓûúÀíÃÜÇÐÏà¹Ø¡£µ«ÊÇ£¬µÝÖÊʧµ÷µÄ±³ºó»úÀí²»ÉõÃ÷ÁË¡£
Ŀǰ£¬ÕâÒ»¼Ù˵ÈÔÈ»´æÔÚÖî¶àÎÊÌâ¡£¾ø´ó¶àÊý¿¹ÒÖÓôÒ©Ö÷ÒªÕë¶Ôµ¥°·×ªÔËÌå°Ðµã£¬Ôö¼ÓÍ»´¥¼ä϶µÄÈ¥¼×ÉöÉÏÏÙËØºÍÎåôÇÉ«°·Ë®Æ½£¬·¢»Ó¿¹ÒÖÓô×÷Óᣵ«ÊÇ£¬¿¹ÒÖÓôÒ©¶Ìʱ¼äÄÚ¼´¿ÉÔö¼ÓÍ»´¥¼ä϶Éñ¾µÝÖÊ£¬¶ø¿¹ÒÖÓôÁÆÐ§È´ÒªÑÓ³Ù2 4ÖÜÏÔʾ[Davis LL£¬WisniewskiSR, Howland RH.Does comorbid substance use disorder impair recovery from majordepression with SSRI treatment An analysis of the STARED level one treatmentoutcomes.Drug Alcohol Depend2010 ; 107 (2-3): 161-170];¿¹ÒÖÓôÒ©µÄ×ÜÓÐЧÂʽöΪ60% 80%£¬ÈÔÓÐÏ൱һ²¿·Ö²¡ÈËȱ·¦ÁÆÐ§»òÓÉÓÚ¶¾¸±·´Ó¦·ÅÆúÖÎÁÆ[Wong ML, LicinioJ.From monoamines to genomic targets:a paradigm shift for drug discovery indepression.Nature Reviews Drug Discovery2004 £»3:136-151];ÒÔÑeºÚËØÎª×÷ÓøïEµã°×É×ÐÂÐÍ¿¹ÒÖÓôÒ©³É¹¦Ñз¢ÉÏÊУ¬½øÒ»²½ËµÃ÷ÒÖÓôÖ¢²¡Òò²¡ÀíµÄ¸´ÔÓÐÔ£¬ËµÃ÷Ŀǰµ¥°·Àà¼Ù˵²»ÄÜÚ¹ÊÍÒÖÓôÖ¢µÄ²¡Àí»úÖÆ£¬´ÙʹÑо¿Õß½øÒ»²½Ì½ÌÖÆä¾ßÌå·¢²¡»úÀí¡£Í¬Ê±£¬ÓÉÓÚÒÖÓôÖ¢ÊÇÒ»ÖÖ·¢×÷ÐԵļ²²¡£¬¾ßÓÐÒ»¶¨µÄ×ÔÓúÇãÏò¡£ÕâÌáʾ£¬ÔÚ»úÌåÄÚ²¿´æÔÚijЩÄÚÔ´ÐԵı£»¤ÒòËØ[Zhang JM, Tonelli L, Regenold WT.Effects of neonatal flutamide treatmenton hippocampal neurogenesis and synaptogenesis correlate with depression-likebehaviors in preadolescent male rats.Neuroscience2010 £»169(1):544-554]¡£¶ÔÓÚÕâЩÄÚÔ´ÐÔ±£»¤ÒòËØµÄ̽ѰҲÐí»á¶ÔÈÏʶÒÖÓôÖ¢·¢²¡»úÀí¡¢×ª¹éºÍÖÎÁƲúÉúÉîÔ¶Ó°Ïì¡£Éñ¾µ÷ÖÊ£¬ÓÈÆäÊÇÓëÐľ³ÕϰÏà¹ØµÄÉñ¾ëÄÀ࣬Öð½¥ÒýÆðÑо¿ÕßµÄ×¢Òâ¡£ÔÚÄÔÄÚ£¬ÕâЩÉñ¾ëij£Óë¾µäµÄÉñ¾µÝÖÊÈçÈ¥¼×ÉöÉÏÏÙËØ¡¢ÎåôÇÉ«°·¡¢¶à°Í°·µÈ¹²´æ¡£ÕâЩµ÷ÖʵÄÒ»¸öÖØÒªÌØÕ÷¾ÍÊÇÔÚÓ¦¼¤×´Ì¬»òÉñ¾Ôª´¦Óڸ߻îÐÔ״̬ϱ»¼¤»î¡£ËûÃÇͨ¹ý¶àÖÖÊÜÌåÑÇÐÍ£¬µ÷½Ú¹²±í´ïÉñ¾ÔªµÄ¹¦ÄܺͻîÐÔ¡£¸Ê±ûëÄÔÚÄÔÄÚ¾ùÓнÏΪ¹ã·ºµÄ·Ö²¼£¬²ÎÓëÈËÌå¶àÖָ߼¶ÉúÀí¹¦Äܵĵ÷½Ú£¬ÈçÈÏÖª¡¢Çé¸ÐÐÐΪ¡¢Éñ¾ËðÉ˵ȡ£ÔÚÖз챳ºËÓÐ95%µÄÎåôÇÉ«°·ÄÜÉñ¾ÔªÓë¸Ê±ûëĵÝÖʹ²´æ£¬À¶°ß80%ÒÔÉϵÄÈ¥¼×ÉöÉÏÏÙËØÄÜÉñ¾ÔªÓë¸Ê±ûëĵÝÖʹ²´æ£»ÎÞÂÛÊÇÀ¶°ß»¹ÊÇÖз챳ºËËùÓеĸʱûëÄÄÜÑôÐÔÉñ¾ÔªÄÚ¾ùÓÐÈ¥¼×ÉöÉÏÏÙËØ»òÎåôÇÉ«°·µÝÖʵĴæÔÚ¡£¸Ê±ûëĵÄÊÜÌåÔÚÀ¶°ßºÍÖз챳ºË²¿Î»¾ùÓбí´ïÇÒÓÐÆäÏËάͶÉä[Kehr J, Yoshitake T£¬Wang FH.Galanin isa potent in vivo modulator of mesencephalic serotonergic neurotransmission.Neuropsychopharmacology2002 £»27 (3):341-356]¡£¸Ê±ûëÄÓëÖз챳ºË´ó²¿·ÖÎåÇáÉ«°·ÄÜÉñ¾ÔªºÍÉ«°±ËáôÇ»¯Ã¸¹²±í ´ï¡£Òò´Ë£¬¸Ê±ûëÄϵͳӰÏìÎåôÇÉ«°·ÄܺÍÈ¥¼×ÉöÉÏÏÙËØÄÜÉñ¾Ôª¹¦ÄÜ¡£»ùÓÚÉÏÊöÑо¿£¬±¾·¢Ã÷Ö÷Ҫͨ¹ýÒÖÓôÖ¢»¼ÕßÌåÄڸʱûëļ°ÐÔ¼¤ËØÓëÒÖÓôÖ¢Ö®¼äµÄ¹ØÁªÐÔ£¬Ì½Ñ°Éñ¾ëÄÓëÐÔ¼¤ËØÏà¹Ø¼¤ËؼäµÄ¹ØÏµ£¬ÎªÅ®ÐÔÒÖÓôÖ¢µÄ¼ì²âÌṩÐµķ½·¨¡£
·¢Ã÷ÄÚÈÝ
±¾·¢Ã÷Ϊ¼ì²âÔ¤·ÀºÍÖÎÁÆÒÖÓôÖ¢¼²²¡£¬Ñо¿ÁËÒÖÓôÖ¢»¼ÕßѪ½¬ÖÐÉñ¾ëÄÓëÒÖÓôÖ¢Ö®¼äµÄ¹ØÁªÐÔ£¬Ñо¿½á¹ûÏÔʾ£¬Ñª½¬ÖиʱûëÄŨ¶ÈÓëÅ®ÐÔÒÖÓôÖ¢ÑÏÖØ³Ì¶È³ÊÏà¹ØÐÔ¡£±¾·¢Ã÷¸ù¾ÝÑо¿ÐèÒªÉ趨ÁËÑù±¾²É¼¯±ê×¼£¬³É¹¦²É¼¯ÁË 700ÃûÒÖÓôÖ¢»¼ÕßµÄѪҺÑù±¾£¬¶ÔÑù±¾½øÐÐÁËÐÔ±ð¡¢ÄêÁä¡¢ÒÖÓô³Ì¶ÈµÈ·½ÃæµÄͳ¼ÆºÍ·Ö²ã¡£ÄêÁä¡¢·¢²¡ÄêÁä¡¢ÌåÖØÖ¸Êý¡¢HAMD¡¢HAMA¼°ÆäÐÔ±ð²îÒì¾ùÎÞÏÔÖøÐÔ²îÒì¡£±¾·¢Ã÷²ÉÓ÷ÅÉäÃâÒߵķ½·¨²â¶¨Ñù±¾Ñª½¬ÖиʱûëĵÈÉñ¾ëĵÄŨ¶È£¬Í³¼ÆÑ§Ñо¿·¢ÏÖÕûÌåÑù±¾ÖиʱûëÄŨ¶ÈÓëÒÖÓôÖ¢ÑÏÖØ³Ì¶È²»´æÔÚÏà¹ØÐÔ£¬¸Ê±ûëÄÓëHAMDÆÀ·ÖÖ®¼äµÄÏà¹ØÏµÊý(r)Ϊ:0.233 (P = 0.084)£¬HAMDΪººÃܶû¶ÙÒÖÓôÁ¿±í¡£
ÐÔ±ð·Ö²ãºóÅ®ÐÔ»¼ÕßѪ½¬¸Ê±ûëÄŨ¶ÈÓëHAMDÆÀ·Ö¡¢¸Ê±ûëÄÓëØºÍªÖ®¼ä´æÔÚÏà¹ØÐÔ£¬Ïà¹ØÏµÊýr·Ö±ðΪ:0.324 (P = 0.046),0.421 (P = 0.014)£¬¶øÄÐÐÔ»¼ÕßѪ½¬¸Ê±ûëÄŨ¶ÈÓëHAMDÆÀ·ÖÎÞÏÔÖøÏà¹ØÐÔ£¬r = -0.68 (P = 0.694)¡£
±¾·¢Ã÷ͨ¹ý¶ÔÒÖÓôÖ¢»¼ÕßѪ½¬¸Ê±ûëÄ¡¢ÐÔ¼¤ËØÏà¹Ø¼¤ËØÓëHAMDÆÀ·ÖµÄÏà¹Ø·ÖÎöÊ״η¢ÏÖ£¬¸Ê±ûëĵÄѪ½¬Å¨¶ÈÓëÅ®ÐÔÒÖÓôÖ¢»¼ÕßµÄHAMDÆÀ·Ö³ÉÕýÏà¹Ø£¬Ïà¹ØÏµÊýΪ0.324 (P = 0.046)¡£ÎÒÃÇ¿ÉÒÔͨ¹ý²â¶¨Å®ÐÔÒÖÓôÖ¢»¼Õ߸ʱûëĵÄѪ½¬Å¨¶ÈÀ´ÍƲâ»òÅжÏÒÖÓôÖ¢×´µÄÑÏÖØÐÔ£¬½ø¶øÎªÒÖÓôÖ¢µÄÁÙ´²ÆÀ¹ÀÌṩÉúÎïѧµÄÖ¸±ê¡£±¾·¢Ã÷ͨ¹ý¶Ô
±¾·¢Ã÷»¹¹«¿ªÁËÒ»ÖÖ¼ì²âÅ®ÐÔÒÖÓôÖ¢µÄÊÔ¼ÁºÐ£¬ÊÔ¼ÁºÐÖаüÀ¨¸Ê±ûëÄ¿¹Ì壬ËùÊö¸Ê±ûëÄ¿¹Ìå¿ÉÒÔͨ¹ýÃâÒß´óÊó¡¢Ð¡Êó¡¢ÍÃ×ӵȲ¸È鶯Î»ñµÃ¸Ê±ûëĶà¿Ë¡¿¹Ì壻Ҳ¿Éͨ¹ý¾µäµÄÔÓ½»Áö¼¼Êõ»ñµÃ¸Ê±ûëĵ¥¿Ë¡¿¹Ìå¡£
±¾·¢Ã÷¹«¿ªÁËÒ»ÖÖ¼ì²âÅ®ÐÔÒÖÓôÖ¢µÄ·ÅÃâÊÔ¼ÁºÐ£¬°üÀ¨ÒÔÏÂ×é·Ý:º¬Galanin¿¹ÌåµÄ´óÊóѪÇå¡¢1251-Galanin(125I±ê¼ÇµÄµÄGalanin)¡¢»º³åÒº¡¢·ÖÀë¼Á¡¢Õý³£´óÊóѪÇå¡¢Galanin±ê׼ƷΪ5¡¢10¡¢20¡¢40¡¢80¡¢160pg/mL ;ËùÊö»º³åҺΪ200mM pH5.0Á×ËáÑλº³åÒº£»ËùÊö·ÖÀë¼ÁΪÍÿ¹´óÊóIgGѪÇå¡£
±¾·¢Ã÷»¹¹«¿ªÁËÒ»ÖÖ¼ì²â¸Ê±ûëĵķ½·¨£¬°üÀ¨ÒÔϲ½Öè:
1¡¢²â¶¨Ç°Ê¹Ñù±¾ÖÃÓÚÊÒλòÀäË®Öи´ÈÚ£¬ÔÙ3000ת/·ÖÀëÐÄ5·ÖÖÓ£¬È¡ÉÏÇåÒº²â¶¨¡£
2¡¢È¡¾Û±½ÒÒÏ©ÊԹܱàºÅ£¬T¡¢NSB£¬S0 S6ºÍ´ý²âÑùÆ·¹ÜµÈ¡£
3¡¢ÆäÖбàºÅΪNSB¹Ü¼Ó»º³åÒº300ul£¬±àºÅΪStl¹Ü¼Ó»º³åÒº200 ¦Ì IºÍº¬Galanin¿¹ÌåµÄ´óÊóѪÇå100 ¦Ì I ;±àºÅΪS1 S6¹ÜÏȼÓ100 ¦Ì I»º³åÒººÍ100 ¦Ì Iº¬Galanin¿¹ÌåµÄ´óÊóѪÇ壬Ȼºó·Ö±ð¼ÓÈë10(^1Ũ¶ÈΪ5¡¢10¡¢20¡¢40¡¢80¡¢16(^/1^µÄ6&1&1^11±ê׼Ʒ£»ÑùÆ·¹Ü¼ÓÈë200ul´ý²âÑù±¾ÉÏÇåºÍ100 ¦Ì Iº¬Galanin¿¹ÌåµÄ´óÊóѪÇ壻ÉÏÊö¸÷¹Ü¼ÓÑùÍê³Éºó³ä·Ö»ìÔÈ£¬ÓÚ4¡ãC£¬·ÅÖÃ24Сʱ¡£
4¡¢ÉÏÊö¸÷¹Ü¼ÓÈë100ul1251-Galanin³ä·Ö»ìÔÈ£¬ÓÚ4¡ãC£¬·ÅÖÃ24Сʱ¡£
5¡¢ÉÏÊö¸÷¹Ü¼ÓÈëIOOulÕý³£´óÊóѪÇ壬³ä·Ö»ì„òºó£¬ÊÒξ²ÖÃ20·ÖÖÓ¡£
6¡¢³ý±ê¼ÇΪTµÄÊÔ¹Ü,ÆäËû¸÷¹Ü¼ÓÈë500ulÍÿ¹´óÊóIgGѪÇå,»ìÔÈ£¬ÊÒηÅÖÃ20·ÖÖÓ£¬4¡ãCÀëÐÄ3500ת/·Ö£¬25·ÖÖÓ£¬Á¢¼´ÎüÈ¡ÉÏÇåÒº£¬²â¶¨¸÷¹Ü³ÁµícpmÊý¡£
7¡¢ÊµÑé½á¹û´¦ÀíÈçÏÂ:
(I)²âÿ·Ý±êÆ·¹ÜµÄcpmÖµ²¢¼ÆËã³öƽ¾ùÊý£»
(2)°´ÏÂÁÐʽ¼ÆËã¸÷±ê×¼¹Ü£¬ÖʿغͲ¡È˱걾µÄB/130%
B/B¡£= (B-NSB)/(B0-NSB) X 100%
B =ΪÑùÆ·¹ÜÖµcpm, B0 =±ê×¼¹ÜB¡£µÄcpmÖµ£»NSB =·ÇÌØÒìÐÔ½áºÏ¹ÜµÄcpmÖµ£»
(3)ÒÔ¸÷±ê×¼¹ÜB/130Ϊ×ÝÖᣬ±ê×¼ÎïŨ¶È(ng/ml)ΪºáÖáÔÚlogit-log×ø±êÖ½ÉÏ»æÖƱê×¼ÇúÏߣ»
(4)ÔÚ±ê×¼ÇúÏßÉϲé³öÖÊ¿ØÑªÇå¼°¸÷±ê±¾µÄ¸Ê±ûëÄŨ¶È¡£
±¾·¢Ã÷ͨ¹ýÉÏÊö·½·¨£¬¼ì²âÁË 376Å®ÐÔµÄѪ½¬¸Ê±ûëÄŨ¶È£¬½á¹ûÏÔʾµ±Å®ÐÔÒÖÓôÖ¢»¼ÕßÒÖÓô³Ì¶È½ÏΪÑÏÖØÊ±£¬ÆäѪ½¬¸Ê±ûëÄŨ¶È³¬¹ý34.54pg/ml ;µ±Å®ÐÔÒÖÓôÖ¢»¼ÕßÒÖÓô³Ì¶ÈΪÖжÈÒÖÓôʱ£¬ÆäѪ½¬¸Ê±ûëÄŨ¶ÈΪ29.73 34.54pg/ml ;µ±Å®ÐÔÒÖÓôÖ¢»¼ÕßÒÖÓô³Ì¶ÈΪÇá¶ÈÒÖÓôʱ£¬ÆäѪ½¬¸Ê±ûëÄŨ¶È´ïΪ23.55 29.73pg/ml ;Õý³£È˵ÄѪ½¬¸Ê±ûëÄŨ¶ÈСÓÚ 21.02pg/ml¡£
¾ßÌåʵʩÀý·½Ê½ÊµÊ©Àý1Ѫ½¬¸Ê±ûëÄŨ¶ÈÓëÒÖÓôÖ¢Ò»¡¢Ñо¿¶ÔÏóºÍ·½·¨1¡¢Ñо¿¶ÔÏóÊ×¶¼Ò½¿Æ´óѧ¸½Êô±±¾©°²¶¨Ò½ÔºÃÅÕï»òסԺµÄ»¼Õß700Àý¡¢·ûºÏDSM-1 VÒÖÓôÖ¢Õï¶Ï±ê×¼£¬²¢·ûºÏÏÂÁбê×¼µÄ»¼Õߣ¬×÷ΪÑо¿¶ÔÏó¡£ÒÖÓôÖ¢»¼ÕßÈë×é±ê×¼:¢ÅסԺ»òÃÅÕﻼÕߣ»(2)ºº×壻(3)ÄêÁä18 60Ëꣻ(4)·ûºÏDSM-1VÒÖÓôÖ¢Õï¶Ï±ê×¼£»(5)»¼Õß±¾ÈË»òÆä·¨Âɼ໤ÈËÇ©ÊðÖªÇéͬÒâÊ飻¡£ÒÖÓôÖ¢»¼ÕßÅųý±ê×¼:(I)Óо«Éñ·ÖÁÑÖ¢¡¢¾Æ¾«ºÍÒ©ÎïÒÀÀµ²¡Ê·£»(2)ÓÐÄÔÆ÷ÖÊÐÔ¼²²¡ºÍÄÚ·ÖÃÚ¼²²¡Ê·£»(3)ÈÑÉïÆÚºÍ²¸È鸾Ů£»(4)ÓÐÔê¿ñ»òÇáÔê¿ñ·¢×÷Ê·£»(5)µçÐÝ¿ËÖÎÁÆÕß¡£2¡¢Ñо¿·½·¨2.1ÁÙ´²×ÊÁÏÊÕ¼¯¶ÔÓÚÉÏÊöÑо¿¶ÔÏó¾ùͨ¹ý2ÃûÖм¶ÒÔÉÏҽʦȷ֤£¬²¢×öSCIDɨÃ裬×ÊÁϲɼ¯°üÀ¨:Ò»°ã°üÀ¨ÄêÁä¡¢ÐÔ±ð¡¢Ãñ×å¡¢ÎÄ»¯³Ì¶È¡¢Ö°Òµ¡¢¼ÈÍù½¡¿µ×´¿ö¡¢Ñ̾ÆÊȺ㬼Ò×åÊ·µÈ£¬¶Ô·ûºÏÈë×éÌõ¼þÕßÇ©ÊðÖªÇéͬÒâÊé¡£ 2.2ÒÖÓôÆÀ¶¨¹¤¾ß¼°·½·¨ÓÉÒ½ÔºÔº¾«Éñ¿Æ5ÃûÓжàÄêÁÙ´²¹¤×÷¼°Á¿±íÆÀ¶¨¾ÑéµÄÖ÷ÖÎÒ½Éú¶ÔËùÓеÄÈë×éÈËÔ±½øÐÐÒ»°ãÇé¿öµÄÁ˽⼰¼òÒ×ÖÇÁ¦×´Ì¬¼ì²é¡¢17ÏÃܶû¶ÙÒÖÓôÁ¿±í(HAMD)ºÍººÃܶû¶Ù½¹ÂÇÁ¿±í(HAMA)À´ÆÀ¶¨»¼ÕßÒÖÓôÖ¢µÄÑÏÖØ³Ì¶È¡£2.3±ê±¾²É¼¯¼°´¦Àí·½·¨¶Ô·ûºÏÈë×éÌõ¼þµÄ»¼Õߣ¬Ô糿6:00µ½9:00Ö®¼ä¿Õ¸¹³éÈ¡Öâ¾²ÂöѪ5ml (EDTA¿¹Äý¹Ü)£¬»ºÂýµ¹ÖÃÊý´Î£¬Ñª½¬µÄ·ÖÀë²ÉÓÃ3000ת/·ÖÀëÐÄ5·ÖÖÓ£¬ÎüÈ¡ÉÏÇåÒº£¬-80¡ãC±£´æ¡£2.4Ѫ½¬Éú»¯Ö¸±ê¼ì²âѪ½¬¸Ê±ûëÄ¡¢Éñ¾ëÄY²â¶¨²ÉÓ÷ÅÃâÊÔ¼ÁºÐ£¬ËÍ301·ÅÃâÑо¿ËùίÍвⶨ¡£Ñª½¬´Æ¼¤ËØ¡¢ÐÛ¼¤ËØ¡¢ÔÐͪ¡¢ØºÍªµÈ²ÉÓû¯Ñ§·¢¹âÃâÒß±ê¼Ç·¨²â¶¨¡£2.4.1¸Ê±ûëÄŨ¶ÈµÄ²â¶¨2.4.1.1ʵÑé²ÄÁϺÍÒÇÆ÷:¸Ê±ûëÄ·ÅÃâÊÔ¼ÁºÐ,¸ßËÙÀä¶³ÀëÐÄ»ú(ÃÀ¹úBeckman¹«Ë¾)¡£ËùÊö¸Ê±ûëÄ·ÅÃâÊÔ¼ÁºÐ°üÀ¨ÒÔÏÂ×é·Ý:º¬Galanin¿¹ÌåµÄ´óÊóѪÇå¡¢1251-Galanin(125I±ê¼ÇµÄµÄGalanin)¡¢»º³åÒº¡¢·ÖÀë¼Á¡¢Õý³£´óÊóѪÇå¡¢Galanin±ê׼ƷΪ5¡¢10¡¢20¡¢40¡¢80¡¢160pg/mL ;ËùÊö»º³åҺΪ200mM pH5.0Á×ËáÑλº³åÒº£»ËùÊö·ÖÀë¼ÁΪÍÿ¹´óÊóIgGѪÇå¡£±¾·¢Ã÷ËùÊöÊÔ¼ÁºÐ¼ì²â¸Ê±ûëĵÄÔÀíÊÇ:Ó¦ÓþºÕù»úÖÆÔÀí£¬±ê׼Ʒ»òÑùÆ·ÖеÄGalaninºÍ¼ÓÈëµÄ1251-Galanin¹²Í¬ÓëÒ»¶¨Á¿µÄ¿¹Galanin¿¹Ìå²úÉú¾ºÕùÐÔÃâÒß·´Ó¦¡£1251-GalaninÓ뿹ÌåµÄ½áºÏÁ¿Óë±ê׼Ʒ»òÑùÆ·ÖÐGalaninµÄº¬Á¿³ÊÒ»¶¨µÄº¯Êý¹ØÏµ¡£ÓÃÃâÒß·ÖÀëÊÔ¼Á(PR)½«½áºÏ²¿·Ö(B)ÓëÓÎÀ벿·Ö(F)·ÖÀëºó£¬²â¶¨½áºÏ²¿·ÖµÄ·ÅÉäÐÔÇ¿¶È£¬²¢¼ÆËãÏàÓ¦½áºÏÂÊB/X¡£ÓÃÒÑÖª±ê×¼Galaninº¬Á¿Óë¶ÔÓ¦½áºÏÂÊ×÷ͼ£¬¼´µÃ±ê×¼ÒÖÖÆÇúÏß¡£´Ó±ê×¼ÇúÏßÉϲéÖª¶ÔÓ¦½áºÏÂʵĴý²âÑùÆ·ÖÐGalaninµÄº¬Á¿¡£
2.4.1.2 ʵÑé²½Öè:
²â¶¨Ç°Ê¹Ñù±¾ÖÃÓÚÊÒλòÀäË®Öи´ÈÚ£¬ÔÙ3000ת/·ÖÀëÐÄ5·ÖÖÓ£¬È¡ÉÏÇåÒº²â¶¨¡£²â¶¨²ÉÓÃ·ÇÆ½ºâ·¨£¬È¡¾Û±½ÒÒÏ©ÊԹܱàºÅ£¬°´±íI²Ù×÷¡£
±íI·ÅÉäÃâÒ߲ⶨ¼ÓÒº³ÌÐò
ȨÀûÒªÇó
1.¸Ê±ûëÄÔÚÖÆ±¸¼ì²âÅ®ÐÔÒÖÓôÖ¢µÄÊÔ¼ÁºÐÖеÄÓ¦Óá£
2.¡ªÖÖ¼ì²âÅ®ÐÔÒÖÓôÖ¢µÄÊÔ¼ÁºÐ,ÆäÌØÕ÷ÔÚÓÚ,ËùÊöÊÔ¼ÁºÐ°üº¬GalaninµÄ¿¹Ìå¡£
3.¡ªÖÖ¼ì²âÅ®ÐÔÒÖÓôÖ¢µÄ·ÅÃâÊÔ¼ÁºÐ£¬ÆäÌØÕ÷ÔÚÓÚ£¬ËùÊöÊÔ¼ÁºÐ°üÀ¨ÒÔÏÂ×é·Ý:º¬Galanin¿¹ÌåµÄ´óÊóѪÇå¡¢1251-Galaniru»º³åÒº¡¢·ÖÀë¼Á¡¢Õý³£´óÊóѪÇå¡¢Galanin±ê׼ƷΪ5¡¢10¡¢20¡¢40¡¢80¡¢160pg/mL ;ËùÊö»º³åҺΪ200mM pH5.0Á×ËáÑλº³åÒº£»ËùÊö·ÖÀë¼ÁΪÍÿ¹´óÊóIgGѪÇå¡£
4.¸ù¾ÝȨÀûÒªÇó2»ò3ÖÐÈÎÒâÒ»ÏîËùÊöµÄÊÔ¼ÁºÐ£¬ÆäÌØÕ÷ÔÚÓÚ£¬ËùÊöµÄ¿¹ÌåΪµ¥¿Ë¡¿¹Ìå¡£
5.¸ù¾ÝȨÀûÒªÇó2»ò3ÖÐÈÎÒâÒ»ÏîËùÊöµÄÊÔ¼ÁºÐ£¬ÆäÌØÕ÷ÔÚÓÚ£¬ËùÊöµÄ¿¹ÌåΪ¶à¿Ë¡¿¹Ìå¡£
6.¸ù¾ÝȨÀûÒªÇó2»ò3ÖÐÈÎÒâÒ»ÏîËùÊöµÄÊÔ¼ÁºÐ£¬ËùÊöµ¥¿Ë¡¿¹ÌåÊÇͨ¹ýÔÓ½»ÁöµÄ·½·¨ÖƱ¸¡£
7.¡ªÖÖ¼ì²â¸Ê±ûëĵķ½·¨£¬°üÀ¨ÒÔϲ½Öè: 1)²â¶¨Ç°Ê¹Ñù±¾ÖÃÓÚÊÒλòÀäË®Öи´ÈÚ£¬ÔÙ3000ת/·ÖÀëÐÄ5·ÖÖÓ£¬È¡ÉÏÇåÒº²â¶¨£» 2)È¡¾Û±½ÒÒÏ©ÊԹܱàºÅ£¬T¡¢NSB£¬SO S6ºÍ´ý²âÑùÆ·¹ÜµÈ£» 3)ÆäÖбàºÅΪNSB¹Ü¼Ó»º³å Òº300ul£¬±àºÅΪStl¹Ü¼Ó»º³åÒº200¦Ì IºÍº¬Galanin¿¹ÌåµÄ´óÊóѪÇå100 ¦Ì I ;±àºÅΪS1 S6¹ÜÏȼÓ100 ¦Ì I»º³åÒººÍ100 ¦Ì Iº¬Galanin¿¹ÌåµÄ´óÊóѪÇ壬Ȼºó·Ö±ð¼ÓÈë10(^1Ũ¶ÈΪ5¡¢10¡¢20¡¢40¡¢80¡¢16(^/1^µÄ6&1&1^11±ê׼Ʒ£»ÑùÆ·¹Ü¼ÓÈë200ul´ý²âÑù±¾ÉÏÇåºÍ100 ¦Ì Iº¬Galanin¿¹ÌåµÄ´óÊóѪÇ壻ÉÏÊö¸÷¹Ü¼ÓÑùÍê³Éºó³ä·Ö»ìÔÈ£¬ÓÚ4¡ãC£¬·ÅÖÃ24Сʱ£» 4)ÉÏÊö¸÷¹Ü¼ÓÈëIOOul1251-Galanin³ä·Ö»ìÔÈ£¬ÓÚ4¡ãC£¬·ÅÖÃ24Сʱ£» 5)ÉÏÊö¸÷¹Ü¼ÓÈëIOOulÕý³£´óÊóѪÇ壬³ä·Ö»ìÔȺó£¬ÊÒξ²ÖÃ20·ÖÖÓ¡£
6)³ý±ê¼ÇΪTµÄÊԹܣ¬ÆäËû¸÷¹Ü¼ÓÈë500ulÍÿ¹´óÊóIgGѪÇ壬»ìÔÈ£¬ÊÒηÅÖÃ20·ÖÖÓ£¬4¡ãCÀëÐÄ3500ת/·Ö£¬25·ÖÖÓ£¬Á¢¼´ÎüÈ¡ÉÏÇåÒº£¬²â¶¨¸÷¹Ü³ÁµícpmÊý¡£
7)ʵÑé½á¹û´¦ÀíÈçÏÂ: (1)²âÿ·Ý±êÆ·¹ÜµÄcpmÖµ²¢¼ÆËã³öƽ¾ùÊý£» (2)°´ÏÂÁÐʽ¼ÆËã¸÷±ê×¼¹Ü£¬ÖʿغͲ¡È˱걾µÄB/130%B/B0 = (B-NSB)/(B0-NSB) X 100% B =ΪÑùÆ·¹ÜÖµcpm, B0 =±ê×¼¹ÜBciµÄcpmÖµ£»NSB =·ÇÌØÒìÐÔ½áºÏ¹ÜµÄcpmÖµ£» (3)ÒÔ¸÷±ê×¼¹ÜB/130Ϊ×ÝÖᣬ±ê×¼ÎïŨ¶È(ng/ml)ΪºáÖáÔÚlogit-log×ø±êÖ½ÉÏ»æÖƱê×¼ÇúÏߣ» (4)ÔÚ±ê×¼ÇúÏßÉϲé³öÖÊ¿ØÑªÇå¼°¸÷±ê±¾µÄ¸Ê±ûëÄŨ¶È¡£
È«ÎÄÕªÒª
±¾·¢Ã÷¹«¿ªÁ˸ʱûëÄÔÚÖÆ±¸Å®ÐÔÒÖÓôÖ¢¼ì²â¹¤¾ßÖеÄÓ¦Ó㬱¾·¢Ã÷ͨ¹ýÑо¿´óÁ¿µÄÁÙ´²ÒÖÓôÖ¢²¡ÈËѪ½¬¸Ê±ûëÄÓëÒÖÓôÖ¢µÄÏà¹ØÐÔ£¬½á¹ûÏÔʾŮÐÔѪ½¬ÖиʱûëĵÄŨ¶ÈÓëÅ®ÐÔÒÖÓôÖ¢µÄŨ¶È³ÊÕýÏà¹Ø¡£±¾·¢Ã÷»¹¹«¿ªÁËÒ»ÖÖ¼ì²âÅ®ÐÔÒÖÓôÖ¢µÄÊÔ¼ÁºÐ¼°ÆäʹÓ÷½·¨¡£
Îĵµ±àºÅG01N33/74GK103175973SQ20131005924
¹«¿ªÈÕ2013Äê6ÔÂ26ÈÕ ÉêÇëÈÕÆÚ2013Äê2ÔÂ26ÈÕ ÓÅÏÈȨÈÕ2013Äê2ÔÂ26ÈÕ
·¢Ã÷ÕßÀî»Û, ÐìÖ¾Çä, Íõ´«Ô¾, ÍõÓÀ¾ü, ÑîÓèÌÎ ÉêÇëÈË:Ê×¶¼Ò½¿Æ´óѧ